Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2011, Article ID 275063, 7 pages
http://dx.doi.org/10.1155/2011/275063
Research Article

Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gonadotropin Subunit to the N-Terminal and C-Terminal Coding Sequence

1Department of Human Biology, Faculty of Natural Sciences, University of Haifa and Department of Molecular Genetics, Carmel Medical Center, Mount Carmel, 31905 Haifa, Israel
2ModigeneTech, Weizmann Science Park, 74140 Nes-Ziona, Israel
3PROLOR Biotech, Weizmann Science Park, 74140 Nes-Ziona, Israel

Received 26 February 2011; Accepted 26 June 2011

Academic Editor: Johannes Vogel

Copyright © 2011 Fuad Fares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Jelkmann, “Erythropoietin: structure, control of production, and function,” Physiological Reviews, vol. 72, no. 2, pp. 449–487, 1992. View at Google Scholar · View at Scopus
  2. S. Schuster, J. H. Wilson, A. J. Erslev, and J. Caro, “Physiologic regulation and tissue localization of renal erythropoietin messenger RNA,” Blood, vol. 70, no. 1, pp. 316–318, 1987. View at Google Scholar · View at Scopus
  3. D. A. Parry, E. Minasian, and S. J. Leach, “Conformational homologies among cytokines: interleukins and colony stimulating factors,” Journal of Molecular Recognition, vol. 1, no. 3, pp. 107–110, 1988. View at Google Scholar · View at Scopus
  4. S. S. Watowich, A. Yoshimura, G. D. Longmore, D. J. Hilton, Y. Yoshimura, and H. F. Lodish, “Homodimerization and constitutive activation of the erythropoietin receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 6, pp. 2140–2144, 1992. View at Google Scholar · View at Scopus
  5. H. Youssoufian, G. Longmore, D. Neumann, A. Yoshimura, and H. F. Lodish, “Structure, function, and activation of the erythropoietin receptor,” Blood, vol. 81, no. 9, pp. 2223–2236, 1993. View at Google Scholar · View at Scopus
  6. J. N. Ihle, “Cytokine receptor signalling,” Nature, vol. 377, no. 6550, pp. 591–594, 1995. View at Google Scholar · View at Scopus
  7. I. Remy, I. A. Wilson, and S. W. Michnick, “Erythropoietin receptor activation by a ligand-induced conformation change,” Science, vol. 283, no. 5404, pp. 990–993, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. L. C. Wasley, G. Timony, P. Murtha et al., “The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin,” Blood, vol. 77, no. 12, pp. 2624–2632, 1991. View at Google Scholar · View at Scopus
  9. K. Jacobs, C. Shoemaker, R. Rudersdorf et al., “Isolation and characterization of genomic and cDNA clones of human erythropoietin,” Nature, vol. 313, no. 6005, pp. 806–810, 1985. View at Google Scholar
  10. F. K. Lin, S. Suggs, C. H. Lin et al., “Cloning and expression of the human erythropoietin gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, pp. 7580–7584, 1985. View at Google Scholar
  11. L. C. Platanias, C. B. Miller, R. Mick et al., “Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients,” Journal of Clinical Oncology, vol. 9, no. 11, pp. 2021–2026, 1991. View at Google Scholar · View at Scopus
  12. D. H. Henry, “Experience with epoetin alfa and acquired immunodeficiency syndrome anemia,” Seminars in Oncology, vol. 25, no. 3, pp. 64–67, 1998. View at Google Scholar · View at Scopus
  13. H. Ludwig, E. Sundal, M. Pecherstorfer et al., “Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy,” Cancer, vol. 76, no. 11, pp. 2319–2329, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. I. C. Macdougall, “Optimizing the use of erythropoietic agents—pharmacokinetic and pharmacodynamic considerations,” Nephrology Dialysis Transplantation, vol. 17, supplement 5, pp. 66–70, 2002. View at Google Scholar · View at Scopus
  15. M. M. Matzuk, A. J. W. Hsueh, P. Lapolt, A. Tsafriri, J. L. Keene, and I. Boime, “The biological role of the carboxyl-terminal extension of human chorionic gonadotropin β-subunit,” Endocrinology, vol. 126, no. 4, pp. 376–383, 1990. View at Google Scholar · View at Scopus
  16. C. J. van den Hamer, A. G. Morell, I. H. Scheinberg, J. Hickman, and G. Ashwell, “Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation,” Journal of Biological Chemistry, vol. 245, no. 17, pp. 4397–4402, 1970. View at Google Scholar · View at Scopus
  17. J. Pierce and T. F. Parsons, “Glycoprotein hormones: structure and function,” Annual Review of Biochemistry, vol. 50, pp. 465–495, 1981. View at Google Scholar · View at Scopus
  18. F. A. Fares, N. Suganuma, K. Nishimori, P. S. LaPolt, A. J. W. Hsueh, and I. Boime, “Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the β chorionic gonadotropin subunit,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4304–4308, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. P. S. Lapolt, K. Nishimori, F. A. Fares, E. Perlas, I. Boime, and A. J. W. Hsueh, “Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl- terminal peptides,” Endocrinology, vol. 131, no. 6, pp. 2514–2520, 1992. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Joshi, Y. Murata, F. E. Wondisford, M. W. Szkudlinski, R. Desai, and B. D. Weintraub, “Recombinant thyrotropin containing a β-subunit chimera with the human chorionic gonadotropin-β carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance,” Endocrinology, vol. 136, pp. 3839–3848, 1994. View at Google Scholar
  21. F. Fares, S. Ganem, T. Hajouj, and E. Agai, “Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of human erythropoietin,” Endocrinology, vol. 148, no. 10, pp. 5081–5087, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Fares, R. Guy, A. Bar-Ilan, Y. Felikman, and E. Fima, “Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of hGH,” Endocrinology, vol. 151, no. 9, pp. 4410–4417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Raves, M. Harel, Y. P. Pang, I. Silman, A. P. Kozikowski, and J. L. Sussman, “Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A,” Nature Structural Biology, vol. 4, no. 1, pp. 57–63, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Kitamura, T. Tange, T. Terasawa et al., “Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin,” Journal of Cellular Physiology, vol. 140, no. 2, pp. 323–334, 1989. View at Google Scholar · View at Scopus
  26. N. Jentoft, “Why are proteins O-glycosylated?” Trends in Biochemical Sciences, vol. 14, no. 8, pp. 272–275, 1990. View at Google Scholar · View at Scopus
  27. L. Wide, “The regulation of metabolic clearance rate of human FSH in mice by variation of the molecular structure of the hormone,” Acta Endocrinologica, vol. 112, no. 3, pp. 336–344, 1986. View at Google Scholar · View at Scopus
  28. J. C. Egrie and J. K. Browne, “Development and characterization of novel erythropoiesis stimulating protein (NESP),” British Journal of Cancer, vol. 84, supplement 1, pp. 3–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Bouloux, D. J. Handelsman, F. Jockenhövel et al., “First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males,” Human Reproduction, vol. 16, no. 8, pp. 1592–1597, 2001. View at Google Scholar
  30. I. J. Duijkers, C. Klipping, P. J. Boerrigter, C. S. M. Machielsen, J. J. de Bie, and G. Voortman, “Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females,” Human Reproduction, vol. 17, no. 8, pp. 1987–1993, 2002. View at Google Scholar · View at Scopus
  31. P. Devroey, B. C. Fauser, P. Platteau, N. G. Beckers, M. Dhont, and B. M. Mannaerts, “Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2062–2070, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. W. Eschbach, J. C. Egrie, M. R. Downing, J. K. Browne, and J. W. Adamson , “Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial,” New England Journal of Medicine, vol. 316, no. 2, pp. 73–78, 1987. View at Google Scholar · View at Scopus
  33. R. W. Evans, B. Rader, and D. L. Manninen, “The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group,” JAMA, vol. 263, no. 6, pp. 825–830, 1990. View at Google Scholar
  34. C. G. Winearls, D. O. Oliver, M. J. Pippard, C. Reid, M. R. Downing, and P. M. Coles, “Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis,” Lancet, vol. 2, no. 8517, pp. 1175–1178, 1986. View at Google Scholar
  35. L. C. Platanias, C. B. Miller, R. Mick et al., “Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients,” Journal of Clinical Oncology, vol. 9, no. 11, pp. 2021–2026, 1991. View at Google Scholar · View at Scopus
  36. H. Ludwig, E. Sundal, M. Pecherstorfer et al., “Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy,” Cancer, vol. 76, no. 11, pp. 2319–2329, 1995. View at Publisher · View at Google Scholar · View at Scopus